GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » Shiller PE Ratio

Can Fite Biofarma (XTAE:CANF) Shiller PE Ratio : (As of May. 16, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Can Fite Biofarma Shiller PE Ratio Historical Data

The historical data trend for Can Fite Biofarma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Shiller PE Ratio Chart

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Can Fite Biofarma's Shiller PE Ratio

For the Biotechnology subindustry, Can Fite Biofarma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Shiller PE Ratio falls into.



Can Fite Biofarma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Can Fite Biofarma's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Can Fite Biofarma's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.019/129.4194*129.4194
=-0.019

Current CPI (Dec. 2023) = 129.4194.

Can Fite Biofarma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.388 99.695 -0.504
201406 -0.372 100.560 -0.479
201409 -0.187 100.428 -0.241
201412 -0.327 99.070 -0.427
201503 -0.056 99.621 -0.073
201506 -0.304 100.684 -0.391
201509 -0.510 100.392 -0.657
201512 0.107 99.792 0.139
201603 -0.204 100.470 -0.263
201606 -0.177 101.688 -0.225
201609 -0.304 101.861 -0.386
201612 -0.417 101.863 -0.530
201703 -0.184 102.862 -0.232
201706 -0.184 103.349 -0.230
201709 -0.147 104.136 -0.183
201712 -0.184 104.011 -0.229
201803 -0.184 105.290 -0.226
201806 -0.110 106.317 -0.134
201809 0.000 106.507 0.000
201812 -0.331 105.998 -0.404
201903 -0.147 107.251 -0.177
201906 -0.113 108.070 -0.135
201909 -0.090 108.329 -0.108
201912 -0.110 108.420 -0.131
202003 -0.110 108.902 -0.131
202006 -0.035 108.767 -0.042
202009 -0.020 109.815 -0.024
202012 0.000 109.897 0.000
202103 -0.014 111.754 -0.016
202106 -0.022 114.631 -0.025
202109 -0.037 115.734 -0.041
202112 -0.037 117.630 -0.041
202203 -0.011 121.301 -0.012
202206 -0.010 125.017 -0.010
202209 -0.016 125.227 -0.017
202212 0.000 125.222 0.000
202303 -0.008 127.348 -0.008
202306 -0.005 128.729 -0.005
202309 -0.005 129.860 -0.005
202312 -0.019 129.419 -0.019

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Can Fite Biofarma  (XTAE:CANF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Can Fite Biofarma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (XTAE:CANF) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (XTAE:CANF) Headlines

From GuruFocus